Genmab shares hit record high on head and neck cancer trial win

· Health · Denmark

Genmab's market value swelled by more than $7 billion after findings showed a recently acquired cancer medicine succeeded in a key trial, sending its shares to record highs. The data suggest the drug could become a new treatment standard for a form of head and neck cancer. The result marks a significant validation of Genmab's acquisition strategy and gives the Danish drugmaker a potential new growth driver. The move came amid a broader burst of cancer-trial news that drove stock moves in both directions over the past 24 hours, with Iovance and Coherus shares tumbling. For investors and oncology developers, the readout raises the bar for competitive programs in head and neck cancer and underscores how pivotal trial data can swing valuations sharply.

Why it matters：A single pivotal readout adding $7 billion in market value shows how decisively oncology data now sets valuations and competitive positioning in cancer drug development.

Key points

  • Market value rose by more than $7 billion.
  • The drug was recently acquired by Genmab.
  • Iovance and Coherus shares fell in the same period.

Sources (original reporting)

More stories from this day